Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial.
J Ribamar Costa, Alexandre Abizaid, Robert Whitbourn, Patrick W Serruys, Nigel Jepson, Clemens Steinwender, Marrianne Stuteville, Divine Ediebah, Krishnankutty Sudhir, Antonio L Bartorelli, undefined ABSORB EXTEND investigators
Catheter Cardiovasc Interv | Published : 2019
BACKGROUND: There is still limited data on the very long term clinical outcomes after ABSORB BRS in daily practice. We sought to evaluate the 3 year-performance of the Absorb bioresorbable vascular scaffolds for the treatment of low/moderate complexity patients enrolled in the ABSORB EXTEND trial. METHODS: ABSORB EXTEND is a prospective, single-arm, open-label clinical study in which 812 patients were enrolled at 56 sites. This study allowed the treatment of lesions ≤28 mm in length and reference vessel diameter of 2.0-3.8 mm (as assessed by on-line QCA). To determine the independent predictors of MACE, a multivariable logistic regression model was built using a stepwise (forward/backward) p..View full abstract